You are here
ADVANCED VISION THERAPIES, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Novel Strategy for BIV Vector Site-Specific Integration
Amount: $349,780.00DESCRIPTION (provided by applicant): Lentivirus-based gene transfer systems represent a promising gene delivery technology, as they integrate into the genome of the target cell and mediate sustained e ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
A Novel BIV vector pseudotyped with thogoto virus gp75
Amount: $149,800.00DESCRIPTION (provided by applicant): Lentivirus-based gene transfer systems represent a promising gene delivery technology, as they integrate into the genome of the target cell and mediate sustained e ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Novel Therapy for Wet Age-Related Macular Degeneration
Amount: $2,160,130.00DESCRIPTION (provided by applicant): Wet age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and represents a disease with a great unmet medical need. The b ...
SBIRPhase II2005Department of Health and Human Services National Institutes of Health -
Evaluation of Kininostatin for Treatment of Wet AMD
Amount: $149,800.00DESCRIPTION: Advanced Vision Therapies, Inc. (AVT) is developing novel therapies for ocular disorders that are the major causes of blindness in the developed world. The initial indications are the ne ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
RdCVF as a novel therapeutic for retinitis pigmentosa
Amount: $311,846.00Advanced Vision Therapies, Inc. (AVT) is developing novel therapies for ocular disorders that are the major causes of blindness in the developed world. These diseases include the neovascular ocular di ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Evaluation of novel BIV-based vectors in primate models
Amount: $541,836.00Advanced Vision Therapies, Inc. (AVT) is developing novel therapies for ocular disorders that are the major causes of blindness in the developed world. These diseases include wet age-related macular d ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Novel Lentiviral Vector with Regulatable Gene Expression
Amount: $133,891.00DESCRIPTION (provided by applicant) Advanced Vision Therapies, Inc. (AV-T) is focused on the treatment of ocular diseases that cause blindness. The primary disease indication is wet age-related macula ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Development of Novel BIV-based Lentiviral Vectors
Amount: $329,702.00DESCRIPTION (provided by applicant): Lentiviral based gene transfer systems represent a promising gene delivery technology due to their ability to efficiently transduce a variety of non-dividing targe ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Novel Therapy for Wet Age-Related Macular Degeneration
Amount: $223,202.00DESCRIPTION (provided by applicant): Wet age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and represents a disease with a great unmet medical need. The b ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health